VILNIUS, Lithuania, Feb. 23, 2021 /PRNewswire/ — Indian cryptocurrency holders can now buy a wide range (+140) of locally redeemable e-gift cards with Bitcoin or other ten cryptocurrency options on CoinGate.

These e-vouchers include some notable brands in India like Flipkart, BigBazaar, SPAR, Arvind, Lifestyle, ALDO, Central, Shoppers Stop, Homecentre, Bata, Pantaloons and more.

All these vouchers and more are in stock and up for grabs on CoinGate's Gift Card store right now. 

All purchased gift cards are sent to the user's provided email address immediately after payment. Get it for yourself, or send it as a gift to someone else directly and instantly.

Your first time paying with crypto? Use these step-by-step instructions to guide you.

India's endlessly growing gift card industry

In India, the gift card market has spread like wildfire over the last couple of years, growing steadily and recording a compound annual growth rate (CAGR) of 25.5% between 2015 and 2019. 

The use of electronic gift cards accelerated even more during COVID-19 outbreak as they proved to be a convenient way to give presents on special occasions while social distancing, or even transfer value across regions without using costly traditional payment channels like banks or money transfer services. 

Looking forward to 2024, India's market for electronic vouchers is estimated to reach 9.34 billion USD in value by then, compared to 3,44 billion USD in 2019 due to their steadily rising popularity and increasing overall adoption in daily lives.

Indian e-gift cards for Bitcoin, Litecoin, Ether & more 

And now, CoinGate is adding fuel to this wildfire by enabling the inventory of more than 140 different e-gift cards for crypto-friendly shoppers from India to obtain using their cryptocurrency portfolios.

Our team is excited to provide India with an opportunity to put their crypto-assets to fair use, knowing that the country is still in limbo about the status of cryptocurrencies which makes them harder to use. 

Now, after almost a year since its Supreme Court struck down RBI banking ban on crypto, Indian traders and exchange operators have new hope for sensible action from the government.

Even though Indian crypto users are struggling to find common ground with traditional payment instruments, we are happy to relieve some pain by providing an easy way to realize cryptocurrency value through gift cards.

Happy spending and hopefully you'll enjoy our service!

Photo – https://mma.prnewswire.com/media/1442308/buy_cryptocurrency_gift_cards_india_coingate.jpg

LONDON, Feb. 23, 2021 /PRNewswire/ — SecurityHQ, the leading provider in managed security services, launch their new Mobile App, SecurityHQ Response.

Cyber never sleeps. Survival demands agility and response demands collaboration, visibility, and action. Which is why SecurityHQ is now part of the few MSSPs that offers an app for clients to handle and respond to incidents anytime, anywhere.

Backed by the power of SecurityHQ's leading Global Security Operation Centres on your mobile device, the new app has significantly advanced the accessibility and visibility of SecurityHQ services and provides a considerable competitive advantage in terms of customer experience and engagement.

With the power of the SOC in the user's hands, interaction, and collaboration has never been easier. Now available on Android and IOS, features are convenient, easy to use, and save the user valuable time. With powerful automation, the app instantly places key information at the user's fingertips. Track the status of security incidents at any time, prioritise and respond to threats, create and search for tickets anywhere, and receive real-time alerts and notifications for security incidents. Call a designated SOC, send emails and receive crucial notifications with the click of a button.

“SecurityHQ have been delivering on its platform for over six years. It has constantly been upgraded to provide our enterprise grade incidence response capabilities, to maintain complete visibility to our clients. The launch of our new mobile app will take all the power of SecurityHQ, onto a fully secured application on your phone, to give clients an incredible reach into their domain, 24/7, at their convenience. The feedback we have had so far has been terrific. Especially with regards to being able to monitor crucial information instantly, while still working remotely.” – Feras Tappuni, CEO, SecurityHQ

Download the App for Android, or IOS.

For more information, view demo video. The product team will be releasing new features and updates later this year. 

SecurityHQ prides itself on its global reputation as an advanced Managed Security Service Provider, delivering superior engineering-led solutions to clients around the world. By combining dedicated security experts, cutting-edge technology and processes, clients receive an enterprise grade experience that ensures that all IT virtual assets, cloud, and traditional infrastructures, are protected.

Website: www.securityhq.com
Facebook: https://www.facebook.com/Sechq
Twitter: https://twitter.com/security_hq
LinkedIn: https://www.linkedin.com/company/securityhq/  

For media enquiries please contact Eleanor Barlow, +44-(0)20-332-706-99, [email protected]

Photo – https://mma.prnewswire.com/media/1440780/SecurityHQ_Response_App.jpg  
Logo – https://mma.prnewswire.com/media/1196748/SecurityHQ_Logo.jpg

• Series C financing brings total capital raised in the last 12 months to over US$ 400 million (>RMB 2.5 billion)
• The proceeds will support the continued development and expansion of Clover's pipeline of protein-based vaccines and biologic cancer therapies

CHENGDU, China, Feb. 22, 2021 /PRNewswire/ — Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics as vaccines and therapeutics for the world's most debilitating diseases, today announced the completion of an oversubscribed $230 million Series C financing. This financing round brings Clover's total capital raised in the last 12 months to over $400 million (over RMB 2.5 billion). The Series C round was co-led by GL Ventures and Temasek, with participation from Oceanpine Capital, OrbiMed and existing investor Delos Capital.

The proceeds will support the continued development and expansion of Clover's pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag^© technology platform. Clover expects to initiate a global Phase 2/3 efficacy trial for SCB-2019 (S-Trimer), its COVID-19 vaccine candidate, in the first half of 2021 and has initiated production planning for potentially hundreds of millions of vaccine doses in 2021. Clover has also initiated development of additional vaccine programs including multivalent SARS-CoV-2 (covering multiple variants), rabies and influenza. SCB-313, a novel TRAIL-Trimer fusion protein targeting intracavitary malignancies (including malignant ascites), is in multiple ongoing Phase I clinical trials in Australia and China, with encouraging efficacy signals and a favorable safety profile demonstrated to-date. Clover also expects to advance multiple new pipeline products to the clinic in 2021 and further expand its in-house R&D and cGMP commercial biomanufacturing capabilities. 

Joshua Liang, Chief Executive Officer and Board Director of Clover said, “Our goal has always been to bring our innovative vaccines and biologic therapies to the world by leveraging our proprietary Trimer-Tag^© platform technology, state-of-the art cGMP biomanufacturing capabilities, and passionate team of over 500 scientists, experienced industry professionals and advisors. We look forward to using the proceeds from this financing round to accelerate development of our pipeline, expand our in-house R&D and biomanufacturing capabilities and move closer to our mission of improving the quality of life and wellbeing for patients around the world.”

Michael Yi, Co-CIO and Partner of Hillhouse Capital, said: “We are pleased to support the continuous development of Clover's promising pipeline, centered on its novel Trimer-Tag^© technology platform. Clover has had a tremendous year of growth with the rapid advancement of the COVID-19 S-Trimer vaccine candidate through clinical development, and we look forward to potentially seeing the Company provide this much-needed vaccine to communities in need across the globe. In addition, Clover's robust and differentiated pipeline of vaccines and biologic therapeutics hold great promise to make a difference in other infectious diseases and oncology indications.”

About Clover Biopharmaceuticals

Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases, as well as viral vaccines. Having raised more than USD $400 million in total capital since 2020, Clover is utilizing its proprietary Trimer-Tag^© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house GMP biomanufacturing capabilities which has been certificated by a Qualified Person (QP) within the European Union (EU) to support GMP production of its biologic products. For more information, please visit our website: www.cloverbiopharma.com.

About Trimer-Tag^© Technology

Trimer-Tag^© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. Many major disease targets are trimerization-dependent such as the tumor necrosis factor (TNF) superfamily (involved in extrinsic apoptosis, immune co-stimulation and inflammation) as well as enveloped RNA virus antigens responsible for entry into host cells. Clover is using its Trimer-Tag^© technology with global IP position to develop recombinant trimerized fusion proteins that can effectively target these previously undruggable pathways.

About GL Ventures

GL Ventures focuses on early-stage innovative companies in healthcare, software services, consumer Internet, emerging consumer brands and services. The GL Ventures team is passionate about partnering with visionary entrepreneurs to create industry leaders that stand the test of time. GL Ventures is the early stage affiliate of Hillhouse Capital, and we have been investing with innovators across the world since 2005. We were one of the earliest investors into some of the largest global companies today, including BeiGene, Zoom, Meituan, JD, Woowa Brothers and many more.

About Temasek

Temasek is an investment company with a net portfolio value of S$306 billion (RMB1.52t) as at 31 March 2020. Our three roles as an Investor, Institution and Steward, as defined in our Temasek Charter, shape our ethos to do well, do right and do good. Our investment philosophy is anchored around four key themes: Transforming Economies; Growing Middle Income Populations; Deepening Comparative Advantages; and Emerging Champions. We actively seek sustainable solutions to address present and future challenges, as we capture investment and other opportunities that help to bring about a better, smarter and more sustainable world. Headquartered in Singapore, we have 11 offices around the world. For more information on Temasek, please visit www.temasek.com.sg.

Clover Biopharmaceuticals Contacts:

Cindy Min
Vice President, Public Affairs
[email protected]

Katelyn Caruso-Sharpe
LifeSci Communications
[email protected]
518-496-6302

View original content to download multimedia:http://www.prnewswire.com/news-releases/clover-biopharmaceuticals-raises-230-million-in-oversubscribed-series-c-financing-301232943.html

SOURCE Clover Biopharmaceuticals